DNA methyltransferase inhibitors for cancer therapy

Area of Science:

• Epigenetics and Cancer Therapeutics

Background:

• Aberrant DNA methylation, particularly hypermethylation of tumor suppressor genes, is a hallmark of many human cancers.
• Epigenetic mutations represent a targetable mechanism in cancer development and progression.
• DNA methyltransferase (DNMT) inhibitors are a class of drugs with the potential to reverse these aberrant epigenetic changes.

Purpose of the Study:

• To explore the therapeutic potential of DNA methyltransferase inhibitors in cancer treatment.
• To highlight the need for molecular markers to monitor epigenetic changes and treatment response in patients undergoing epigenetic therapy.
• To discuss the feasibility of developing novel, small molecule DNMT inhibitors for improved cancer therapies.

Main Methods:

• Review of current clinical trials utilizing azanucleosides for epigenetic therapy in leukemias and other tumors.
• Discussion of recent advancements in the rational design of small molecule DNMT inhibitors.
• Emphasis on the importance of monitoring drug-induced DNA methylation changes in clinical settings.

Main Results:

• Epigenetic therapies using DNMT inhibitors show promise for reversing cancer-associated DNA methylation.
• The development of novel small molecule DNMT inhibitors is feasible and progressing.
• Clinical trials are underway to evaluate azanucleosides for cancer treatment.

Conclusions:

• DNA methyltransferase inhibitors represent a promising avenue for novel epigenetic cancer therapies.
• Monitoring epigenetic changes during treatment is crucial for optimizing therapeutic outcomes.
• Continued development of targeted DNMT inhibitors and robust monitoring strategies will advance epigenetic cancer treatment.